Compare Broadcom Inc (AVGO) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Broadcom Inc vs Revvity Inc — how do they compare? Broadcom Inc trades at $388.99 (market cap $1.85T), while Revvity Inc trades at $111.64 (market cap $12.41B). The key difference: Broadcom Inc is far larger — about 149.1× Revvity Inc's market cap, and Broadcom Inc pays the higher dividend (0.67%). Which is the better fit depends on your goals.
| AVGO | RVTY | |
|---|---|---|
Market Cap | $1.85T | $12.41B |
Sector | Technology | Technology |
52-Week High | $481.57 | $117.75 |
52-Week Low | $278.59 | $82.26 |
Enterprise Value | $1.90T | $14.90B |
Dividend Yield | 0.67% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Broadcom (AVGO) trades at $384.05, down 3.98% on the day, but maintains strong fundamental momentum with consistent earnings beats and robust revenue growth. The stock shows bullish technical signals with support at $380 and resistance at $392, while fundamentals reveal impressive profitability with 38.85% net margins and 37.28% ROE. Recent analyst coverage remains overwhelmingly positive with 86% buy ratings.
AVGO presents a compelling growth story with AI-driven revenue expansion and strong cash flow generation, though elevated valuation multiples (P/E 63.9) and high debt levels warrant caution. The consensus price target of $509.70 suggests significant upside potential if execution continues, but investors should monitor competitive pressures in the semiconductor space.
RVTY trades at $111.11, down 1.05% today, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.06 exceeding expectations. Recent developments include AI integration with Anthropic's Claude and FDA clearance for a testosterone assay, signaling innovation in diagnostics and life sciences.
The outlook remains positive with strong analyst support (51.72% buy ratings) and a consensus price target of $111.43. Key risks include margin pressure from China divestment plans and weak academic demand. Revenue stability around $2.9B supports valuation, though high P/E of 53.47 requires sustained growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
